跳至主要内容
临床试验/JPRN-jRCTs041190038
JPRN-jRCTs041190038招募中2 期

An open-label, randomized, clinical trial of dasatinib vs. nilotinib in the treatment of children with chronic and accelerated phase chronic myeloid leukemia. - JPLSG-CML-17

Keino Dai0 个研究点目标入组 65 人开始时间: 2019年6月6日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
65

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 < 18age old(—)
性别
All

入选标准

  • 1) prior enrollment to JPLSG-CHM-14 study
  • 2) BCR-ABL1 positive CML
  • 3) chronic or accelerated phase at diagnosis and no history of disease progression
  • 4) patients who have no history of TKI treatment other than imatinib or who are imatinib-resistant and/or intolerant
  • 5) < 18 years of age at enrollment
  • 6) ECOG PS 0-2 (CML-related PS 3 is allowed)
  • 7) written informed consent obtained from patient and/or guardian

排除标准

  • 1) previously documented highly resistant mutations to dasatinib and/or nilotinib
  • 2) QTcF >=0.45 second
  • 3) pregnant or lactating female including who plans to be pregnant during clinical trial
  • 4) positive allergic history to excipients of dasatinib or nilotinib
  • 5) prior allogeneic hematopoietic stem cell transplantation for CML
  • 6) uncontrolled or sever comorbidities
  • 7) patients who are ineligible decided by pediatricians

研究者

发起方
Keino Dai

相似试验

A clinical trial of dasatinib vs. nilotinib in... | 临床试验